Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence?

Vaccine

Volumn 35, Issue 27, 2017, Pages 3452-3456

  Gessner, Bradford D ^a   Halsey, Neal ^b  

^a Agence de Medecine Preventive   (France)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adverse events following immunization; Clinical trial; Dengue; Immunization; Safety; Vaccine

Indexed keywords

DENGUE VACCINE;

ADOLESCENT; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; IMMUNITY; PRIORITY JOURNAL; DENGUE; FEMALE; FOLLOW UP; IMMUNOLOGY; INCIDENCE; MALE; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE;

EID: 85019354473     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.05.003     Document Type: Article

References (15)

1. Sabachareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., et al. Protective efficacy of the recombinant, live-attenuated CYD tetravalent dengue vaccine in Thai schoolchildren: a randomized, controlled phase 2b trial. Lancet 380 (2012), 1559–1567.
2. Hadinegoro, S.R., Arredondo-Garcia, J.L., Capding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
3. SAGE Working Group on Dengue Vaccines and WHO Secretariat. Background paper on dengue vaccines. 17 March 2016. Available at website: < http://www.who.int/immunization/sage/meetings/2016/april/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf> (last accessed 17 October 2016).
4. Halstead, S.B., Russell, P.K., Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34 (2016), 1643–1647.
5. Hadinegoro, S.R., Arredondo-García, J.L., Guy, B., Bouckenooghe, A., Noriega, F., Jackson, N., Answer to the review from Halstead and Russell “Protective and immunological behavior of chimeric yellow fever dengue vaccine”. Vaccine 34 (2016), 4273–4274.
6. Endy, T.P., Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Front Immunol, 5, 2014, 183.
7. Anderson, K.B., Gibbons, R.V., Cummings, D.A., Nisalak, A., Green, S., Libraty, D.H., et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 209 (2014), 360–368.
8. Ferguson, N.M., Rodriguez-Barraquer, I., Dorigatti, I., Mier-Y-Teran-Romero, L., Laydon, D.J., Cummings, D.A., Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science 353 (2016), 1033–1036.
9. Gailhardou, S., Skipetrova, A., Daya, G.H., Jezorwski, J., Saville, M., Van der Viliet, D., et al. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. PLoS Negl Trop Dis, 10, 2016, e0004821.
10. Wilder-Smith, A., Vannice, K.S., Hombach, J., Farrar, J., Nolan, T., Population perspective and World Health Organization recommendations for CYD-TDV dengue vaccine. J Infect Dis 214 (2016), 1796–1799.
11. Gessner, B.D., Wilder-Smith, A., Estimating the public health importance of the CYD-tetravalent dengue vaccine: vaccine preventable disease incidence and numbers needed to vaccinate. Vaccine 34 (2016), 2397–2401.
12. World Health Organization, Dengue vaccine: WHO position paper – July 2016. Weekly Epidemiol Rev 91 (2016), 349–364.
13. World Health Organization, Global advisory committee on vaccine safety, 15–16 June 2016. Weekly Epidemiol Rev, 91(341–8), 2016, 18.
14. Dorigatti, I., Aguas, R., Donnelly, C.A., Guy, B., Coudeville, L., Jackson, N., et al. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine 33 (2015), 3746–3751.
15. RTS,S Clinical Trials Partnership, Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individual randomized, controlled trial. Lancet 386 (2015), 31–45.